Prestige Consumer Healthcare Inc. agreed to acquire the Breathe Right brand and other assets for $1.045 billion.
The net purchase price is estimated at $900 million. This figure accounts for $150 million in expected tax benefits. The portfolio includes the Dimetapp and Anbesol brands acquired from Foundation Consumer Healthcare.
The acquired brands generated $200 million in revenue for the twelve months ending December 31, 2025. The portfolio produced $95 million in EBITDA during that same period. Prestige expects the acquisition to be immediately accretive to revenue growth and profit margins.
The company will fund the deal with cash on hand and a new term loan. The transaction is scheduled to close in the first half of Prestige's fiscal year 2027. The deal is currently pending regulatory approval.